Pfizer

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Pfizer 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PFE

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. 

CEO
Albert Bourla
CEOAlbert Bourla
Employees
75,000
Employees75,000
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
1849
Founded1849
Employees
75,000
Employees75,000

PFE Key Statistics

Market cap
157.20B
Market cap157.20B
Price-Earnings ratio
40.13
Price-Earnings ratio40.13
Dividend yield
6.13%
Dividend yield6.13%
Average volume
35.23M
Average volume35.23M
High today
$27.99
High today$27.99
Low today
$27.44
Low today$27.44
Open price
$27.91
Open price$27.91
Volume
35.53M
Volume35.53M
52 Week high
$31.44
52 Week high$31.44
52 Week low
$23.62
52 Week low$23.62

Stock Snapshot

As of today, Pfizer(PFE) shares are valued at $27.59. The company's market cap stands at 157.2B, with a P/E ratio of 40.13 and a dividend yield of 6.13%.

On 2026-11-20, Pfizer(PFE) stock moved within a range of $27.44 to $27.99. With shares now at $27.59, the stock is trading +0.5% above its intraday low and -1.4% below the session's peak.

Trading activity shows a volume of 35.53M, compared to an average daily volume of 35.23M.

Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $31.44 and a low of $23.62.

Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $31.44 and a low of $23.62.

PFE News

Seeking Alpha 10h
Bipartisan panel says China 'doubling down' on control of pharma supply chain

Bipartisan panel says China 'doubling down' on control of pharma supply chain Nov 19, 2026, 4:09 PM ET Pfizer Inc. (PFE) Stock, NVS Stock, AZN Stock, GSK Stock,...

Bipartisan panel says China 'doubling down' on control of pharma supply chain
TipRanks 15h
Pfizer Advances Phase 3 Trial of Berobenatide for Women With Incontinence and Excess Weight

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Study Overview: Pfizer’s VESPER-SUI study is officially titled “A Phase 3, Randomized, Do...

TipRanks 15h
Pfizer Updates Real-World Migraine Study as Investors Watch Nurtec’s Staying Power

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Study Overview: Pfizer’s CORRELATE-UK study, officially titled CORRELATE-UK: COnsistency...

Analyst ratings

61%

of 28 ratings
Buy
28.6%
Hold
60.7%
Sell
10.7%

More PFE News

Simply Wall St 15h
Missed Pfizer's Rally? Here Is What Holders Saw - Simply Wall St

...

Missed Pfizer's Rally? Here Is What Holders Saw - Simply Wall St
24/7 Wall St. 15h
Invest $400,000 in These 4 Dividend Stocks Yielding Over 6% for Retirement Income

It sounds nuts, but SoFi is giving new Active Invest users up to $1,000 in stock for a limited time, and all it takes is a $50 deposit to get started. See for y...

Invest $400,000 in These 4 Dividend Stocks Yielding Over 6% for Retirement Income
Zacks 17h
Can New Products and Acquisitions Revive Pfizer's Growth Story?

Pfizer's (PFE Quick QuotePFE - Free Report) business mix has changed significantly over the past few years. During the pandemic, the company became heavil...

Can New Products and Acquisitions Revive Pfizer's Growth Story?
The Motley Fool 21h
Pfizer Will Pay Its 352nd Straight Quarterly Dividend on Dec. 7. Here's What It Would Take to Break the Streak.

Free Article Explore Premium Services Pfizer Will Pay Its 352nd Straight Quarterly Dividend on Dec. 7. Here's What It Would Take to Break the Streak. Pfizer's d...

Pfizer Will Pay Its 352nd Straight Quarterly Dividend on Dec. 7. Here's What It Would Take to Break the Streak.
TipRanks 2d
H.C. Wainwright positive on Legend Biotech after Pfizer CAR-T deal

H.C. Wainwright reiterates a Buy rating on Legend Biotech (LEGN) with a $65 price target after Pfizer (PFE) announced an agreement to license three in vivo CAR-...

Benzinga 2d
Pfizer Strikes Multibillion-Dollar Deal to Take on Autoimmune Diseases

Pfizer Inc. (NYSE:PFE) announced Wednesday an exclusive licensing agreement with Starna Therapeutics worth up to $2.63 billion in upfront and milestone payments...

Pfizer Strikes Multibillion-Dollar Deal to Take on Autoimmune Diseases
Seeking Alpha 2d
Pfizer, Starna ink cell therapy licensing deal worth up to $2.6B

Pfizer (PFE) on Wednesday announced an exclusive licensing agreement with China-based RNA medicines company Starna Therapeutics to develop and commercialize chi...

Pfizer, Starna ink cell therapy licensing deal worth up to $2.6B

People also own

Based on the portfolios of people who own PFE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.